GraniteShares Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$640K Sell
7,074
-1,473
-17% -$123K 0.41% 67
2026
Q1
$684K Sell
8,547
-1,398
-14% -$115K 0.49% 62
2025
Q4
$848K Buy
9,945
+443
+5% +$36.4K 0.51% 62
2025
Q3
$739K Buy
9,502
+172
+2% +$13.4K 0.43% 69
2025
Q2
$730K Sell
9,330
-509
-5% -$38K 0.45% 69
2025
Q1
$713K Sell
9,839
-515
-5% -$36.9K 0.45% 65
2024
Q4
$767K Sell
10,354
-2,132
-17% -$149K 0.49% 66
2024
Q3
$824K Buy
12,486
+1,399
+13% +$102K 0.56% 67
2024
Q2
$1.02M Buy
11,087
+1,091
+11% +$96.6K 0.34% 60
2024
Q1
$955K Sell
9,996
-597
-6% -$50.1K 0.51% 65
2023
Q4
$808K Sell
10,593
-825
-7% -$57.4K 0.73% 65
2023
Q3
$791K Buy
+11,418
New +$918K 0.74% 64
2022
Q3
Sell
-2,358
Closed -$224K 139
2022
Q2
$224K Sell
2,358
-494
-17% -$51.1K 0.16% 132
2022
Q1
$335K Sell
2,852
-93
-3% -$10.4K 0.18% 126
2021
Q4
$381K Buy
+2,945
New +$344K 0.18% 127

Other funds holding EW

GraniteShares Advisors's EW Position: Q2 2026 in Review

GraniteShares Advisors reduced its Edwards Lifesciences (EW) stake by 17% in Q2 2026, selling an estimated $123K and leaving 7,074 shares worth $640K. The position accounts for 0.41% of the portfolio, ranked #67.

GraniteShares Advisors first reported a position in EW in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.02M in Q2 2024. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • GraniteShares Advisors held 7,074 shares of Edwards Lifesciences worth $640K as of Q2 2026.
  • GraniteShares Advisors sold 1,473 Edwards Lifesciences shares in Q2 2026, an estimated $123K.
  • Edwards Lifesciences made up 0.41% of GraniteShares Advisors's portfolio in Q2 2026, its #67 holding.
  • GraniteShares Advisors first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 15 quarters since.
  • GraniteShares Advisors's Edwards Lifesciences position peaked at $1.02M in Q2 2024.
  • 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on GraniteShares Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.